Zudena (udenafil) is a phosphodiesterase type 5 (PDE5) inhibitor specifically developed for the treatment of erectile dysfunction (ED). As a selective and potent agent, it offers a reliable therapeutic option with a favorable pharmacokinetic profile, including rapid onset and sustained duration of action. This medication is designed to improve erectile function by enhancing blood flow to the corpus cavernosum, facilitating natural sexual response. It is indicated for adult males experiencing difficulties in achieving or maintaining an erection sufficient for satisfactory sexual performance.

Features

• Active ingredient: Udenafil 100 mg
• Mechanism: Selective PDE5 inhibition
• Onset of action: Approximately 30–60 minutes
• Duration of effect: Up to 12 hours
• Administration: Oral tablet, taken as needed
• Compatibility: Can be taken with or without food

Benefits

• Provides a extended window of opportunity for sexual activity, reducing time-related anxiety.
• Demonstrates high efficacy in clinical trials for improving erectile function across various ED severities.
• Offers flexibility with or without food intake, minimizing lifestyle disruption.
• Exhibits a favorable safety and tolerability profile with low incidence of adverse events.
• Supports natural sexual stimulation, requiring arousal for effect.
• May improve patient confidence and relationship satisfaction through reliable performance.

Common use

Zudena is prescribed for the management of erectile dysfunction in adult men. It is used on an as-needed basis to facilitate erections adequate for sexual intercourse. Clinical use is supported by evidence in patients with organic, psychogenic, or mixed etiology ED. It is not intended for use in women, children, or adolescents.

Dosage and direction

The recommended dose is 100 mg taken orally approximately 30–60 minutes before anticipated sexual activity. Dosage may be adjusted based on efficacy and tolerability, under medical supervision. Do not exceed one dose per 24-hour period. Tablets should be swallowed whole with water; crushing or splitting is not advised.

Precautions

• Not for use in patients with known hypersensitivity to udenafil or any excipients.
• Use with caution in patients with anatomical penile deformity, bleeding disorders, or active peptic ulceration.
• Cardiovascular status should be assessed prior to initiation, as sexual activity carries potential cardiac risk.
• Avoid concurrent use with other ED treatments or recreational drugs containing nitrates.
• Priapism (prolonged erection >4 hours) requires immediate medical attention to avoid permanent damage.
• Discontinue use and seek medical advice if sudden vision or hearing loss occurs.

Contraindications

• Concomitant use with organic nitrates or nitric oxide donors in any form.
• History of non-arteritic anterior ischemic optic neuropathy (NAION).
• Severe hepatic impairment (Child-Pugh Class C).
• Severe cardiovascular disorders where sexual activity is not recommended.
• Hypersensitivity to any component of the formulation.

Possible side effects

Common adverse reactions (≥1/100 to <1/10) include headache, flushing, nasal congestion, dyspepsia, and dizziness. Less frequently (≥1/1,000 to <1/100), blurred vision, palpitations, back pain, or myalgia may occur. In rare instances (<1/1,000), serious effects such as priapism, sudden hearing loss, or cardiovascular events have been reported.

Drug interaction

• Absolute contraindication with nitrates due to risk of severe hypotension.
• Caution with alpha-blockers (additive hypotensive effects).
• Potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase udenafil exposure—dose adjustment may be needed.
• Grapefruit juice may increase plasma concentrations and should be avoided.
• Interaction with antihypertensives may potentiate blood pressure-lowering effects.

Missed dose

Zudena is taken on an as-needed basis; there is no scheduled dosing. If a dose is missed, it may be taken when remembered, provided it is at least 24 hours before the next anticipated sexual activity. Do not double the dose.

Overdose

In case of suspected overdose, symptomatic management is advised. Expected effects may include severe hypotension, syncope, or prolonged erection. Supportive measures should be initiated, including cardiovascular monitoring. Priapism requires urgent urological intervention. Dialysis is not expected to significantly enhance elimination.

Storage

Store below 30°C (86°F) in the original packaging, protected from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.

Disclaimer

This information is intended for healthcare professionals and patients under medical supervision. It is not exhaustive and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personalized recommendations and to discuss potential risks and benefits based on individual health status and history.

Reviews

Clinical studies and post-marketing surveillance indicate high patient satisfaction with Zudena, particularly regarding its extended duration of action and reliability. Many users report improved confidence and sexual performance. Healthcare providers note its predictable pharmacokinetics and generally mild side effect profile, making it a suitable option within the PDE5 inhibitor class.